Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia

被引：20

作者：

Ivanov, Vladimir ^{[1
]}

Yeh, Su-Peng ^{[2
]}

Mayer, Jiri ^{[3
,4
]}

Saini, Lalit ^{[5
]}

Unal, Ali ^{[6
]}

Boyiadzis, Michael ^{[7
]}

Hoffman, David M. ^{[8
]}

Kang, Kingston ^{[8
]}

Addo, Sadiya N. ^{[8
]}

Mendes, Wellington L. ^{[8
]}

Fathi, Amir T. ^{[9
]}

机构：

[1] Almazov Natl Med Res Ctr, St Petersburg, Russia

[2] China Med Univ Hosp, Taichung, Taiwan

[3] Fak Nemocnice Brno, Brno, Czech Republic

[4] Masaryk Univ, Brno, Czech Republic

[5] London Hlth Sci Ctr, London, ON, Canada

[6] Erciyes Univ, Sch Med, Kayseri, Turkey

[7] Genentech Inc, San Francisco, CA USA

[8] AbbVie Inc, N Chicago, IL USA

[9] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA

来源：

FUTURE ONCOLOGY | 2022年 / 18卷 / 26期

关键词：

acute myeloid leukemia; BCL-2; inhibitor; CC-486 (oral azacitidine); first remission; maintenance therapy; minimal residual disease conversion; phase III; relapse-free survival; venetoclax; QUALITY-OF-LIFE; HEMATOPOIETIC-CELL TRANSPLANTATION; CONVENTIONAL CARE REGIMENS; LOW-DOSE CYTARABINE; OLDER PATIENTS; COMPLETE REMISSION; ELDERLY-PATIENTS; POSTREMISSION TREATMENT; TREATMENT OUTCOMES; BCL-2; INHIBITION;

D O I：

10.2217/fon-2022-0450

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Prevention of relapse is a major therapeutic challenge and an unmet need for patients with acute myeloid leukemia (AML). Venetoclax is a highly selective, potent, oral BCL-2 inhibitor that induces apoptosis in AML cells. When combined with azacitidine, it leads to prolonged overall survival and rapid, durable remissions in treatment-naive AML patients ineligible for intensive chemotherapy. VIALE-M is a randomized, double-blind, two-arm study to evaluate the safety and efficacy of venetoclax in combination with oral azacitidine (CC-486) as maintenance therapy in patients in complete remission with incomplete blood count recovery after intensive induction and consolidation therapies. The primary end point is relapse-free survival. Secondary outcomes include overall survival, minimal residual disease conversion and improvement in quality-of-life.

引用

页码：2879 / 2889

页数：11

共 50 条

[41] Incidence of Tumour Lysis Syndrome in Patients with Acute Myeloid Leukemia During Initiation of Therapy with Azacitidine and Venetoclax: A Retrospective Chart Review from a Canadian Single-Centre Perspective [J].

Saiyin, Tana ;

Christou, Grace ;

Sabloff, Mitchell ;

Crosbie, Tina ;

Nguyen-Tham, Kim-My ;

Fulcher, Jill .

CURRENT ONCOLOGY, 2025, 32 (04)

[42] A phase ib clinical trial of oral ciprofloxacin and etoposide in subjects with resistant acute myeloid leukemia [J].

Gera, Kriti ;

Cline, Christina ;

Al-Mansour, Zeina ;

Medvec, Andrew ;

Lee, Ji-Hyun ;

Galochkina, Zhanna ;

Hsu, Jack ;

Hiemenz, John ;

Farhadfar, Nosha ;

Dean, Erin A. ;

Wingard, John R. ;

Brown, Randy .

LEUKEMIA & LYMPHOMA, 2024, 65 (10) :1502-1510

[43] Assessment of the consistency and robustness of results from a multicenter trial of remission maintenance therapy for acute myeloid leukemia [J].

Marc Buyse ;

Pierre Squifflet ;

Kathryn J Lucchesi ;

Mats L Brune ;

Sylvie Castaigne ;

Jacob M Rowe .

Trials, 12

[44] Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial [J].

Dohner, Hartmut ;

Symeonidis, Argiris ;

Deeren, Dries ;

Demeter, Judit ;

Sanz, Miguel A. ;

Anagnostopoulos, Achilles ;

Esteve, Jordi ;

Fiedler, Walter ;

Porkka, Kimmo ;

Kim, Hee-Je ;

Lee, Je-Hwan ;

Usuki, Kensuke ;

D'Ardia, Stefano ;

Won Jung, Chul ;

Salamero, Olga ;

Horst, Heinz-August ;

Recher, Christian ;

Rousselot, Philippe ;

Sandhu, Irwindeep ;

Theunissen, Koen ;

Thol, Felicitas ;

Dohner, Konstanze ;

Teleanu, Veronica ;

DeAngelo, Daniel J. ;

Naoe, Tomoki ;

Sekeres, Mikkael A. ;

Belsack, Valerie ;

Ge, Miaomiao ;

Taube, Tillmann ;

Ottmann, Oliver G. .

HEMASPHERE, 2021, 5 (08) :E617

[45] First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab plus Azacitidine plus Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML) [J].

Zeidan, Amer M. ;

Westermann, Joerg ;

Kovacsovics, Tibor ;

Assouline, Sarit ;

Schuh, Andre C. ;

Kim, Hee-Je ;

Macias, Gabriela Rodriguez ;

Sanford, David ;

Luskin, Marlise R. ;

Stein, Eytan M. ;

Malek, Kamel ;

Lyu, Jiaying ;

Stegert, Mario ;

Esteve, Jordi .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 :S255-S255

[46] Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome [J].

Raffoux, Emmanuel ;

Cras, Audrey ;

Recher, Christian ;

Boelle, Pierre-Yves ;

de Labarthe, Adrienne ;

Turlure, Pascal ;

Marolleau, Jean-Pierre ;

Reman, Oumedaly ;

Gardin, Claude ;

Victor, Maud ;

Maury, Sebastien ;

Rousselot, Philippe ;

Malfuson, Jean-Valere ;

Maarek, Odile ;

Daniel, Marie-Therese ;

Fenaux, Pierre ;

Degos, Laurent ;

Chomienne, Christine ;

Chevret, Sylvie ;

Dombret, Herve .

ONCOTARGET, 2010, 1 (01) :34-42

[47] A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients [J].

Bouabdallah, R ;

Lefrère, F ;

Rose, C ;

Chaïbi, P ;

Harousseau, JL ;

Vernant, JP ;

Castaigne, S ;

Bauduer, F ;

Zini, JM ;

Coso, D ;

Varet, B ;

Robert, J ;

Fenaux, P .

LEUKEMIA, 1999, 13 (10) :1491-1496

[48] A phase II trial of induction and consolidation therapy of acute myeloid leukemia with weekly oral idarubicin alone in poor risk elderly patients [J].

R Bouabdallah ;

F Lefrère ;

C Rose ;

P Chaïbi ;

J-L Harousseau ;

J-P Vernant ;

S Castaigne ;

F Bauduer ;

J-M Zini ;

D Coso ;

B Varet ;

J Robert ;

P Fenaux .

Leukemia, 1999, 13 :1491-1496

[49] Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial [J].

Luger, Selina M. ;

Wang, Victoria X. ;

Rowe, Jacob M. ;

Litzow, Mark R. ;

Paietta, Elisabeth ;

Ketterling, Rhett P. ;

Lazarus, Hillard ;

Rybka, Witold B. ;

Craig, Michael D. ;

Karp, Judith ;

Cooper, Brenda W. ;

Makary, Adel Z. ;

Kaminer, Lynne S. ;

Appelbaum, Frederick R. ;

Larson, Richard A. ;

Tallman, Martin S. .

LEUKEMIA RESEARCH, 2021, 111

[50] Findings From an Analysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia (AML), Including AML-M4 and AML-M5, Treated With Venetoclax (Ven) Plus Azacitidine (Aza) [J].

Konopleva, Marina ;

DiNardo, Courtney ;

Sun, Yan ;

Loghavi, Sanam ;

Jung, Paul ;

Potluri, Jalaja ;

Dail, Monique ;

Chyla, Brenda ;

Pollyea, Daniel .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 :S266-S267

← 1 2 3 4 5 →